LANTHEUS HOLDINGS, INC. Funds and ETFs Lantheus Holdings, Inc.
Equities
LNTH
US5165441032
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.56 USD | +0.55% |
|
+2.74% | +5.74% |
| Apr. 18 | B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating | MT |
| Mar. 07 | Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing | MT |
ETFs positioned on Lantheus Holdings, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.58% | 16 M€ | -8.49% | ||
| 1.30% | 12 M€ | -.--% | - | |
| 0.12% | 237 M€ | +2.89% | - | |
| 0.07% | 773 M€ | -.--% | - | |
| 0.05% | 9 M€ | -.--% | - | |
| 0.04% | 9 M€ | +6.26% | - | |
| 0.03% | 20 M€ | -.--% | - | |
| 0.02% | 33 M€ | +0.25% | - | |
| 0.02% | 18 M€ | +3.41% | - | |
| 0.02% | 8 M€ | +3.41% | - | |
| 0.01% | 147 M€ | +4.88% | - | |
| 0.01% | 18 M€ | +3.86% | - | |
| 0.00% | 34 M€ | +2.14% | - |
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
65.56
USD
Average target price
94.11
USD
Spread / Average Target
+43.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.74% | 4.49B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- LNTH Stock
- Funds and ETFs Lantheus Holdings, Inc.
